Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sophie Betteridge


I joined the Oncology Clinical Trials Office (OCTO) as a Trial Manager in  November 2018.  Before this I worked for 5 years in the Centre of Trials Research at Cardiff University as a Trial Manager working on International Acute Myeloid Leukaemia studies.

I am currently working on the WINGMEN trial –  a Phase 0 study of IGF antibody xentuzumab in men with prostate cancer in the 3-4-week window prior to their scheduled radical prostatectomy.  The trial will test the feasibility of recruiting men with early prostate cancer, the tolerability of xentuzumab in the pre-operative setting, and will provide pre- and post- treatment samples for assessment of circulating and tissue markers of prostate cancer progression.  If effective at downregulating mediators of high IGF-1, this approach has potential to be tested for its ability to reduce the need for radical treatment in men with small cancers on active surveillance. The long-term aims are to prevent prostate cancer progression, identify biomarkers to predict who will benefit from IGF blockade, and identify key mediators that may be targets for risk reduction.